Univariate and multivariate Cox regression analysis for progression-free survival
| Factor | Univariate analysis | Multivariate analysis | ||||||
| Number | Number of events | HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age (years) | ||||||||
| <65 | 43 | 8 | 1 | |||||
| ≥65 | 11 | 4 | 2.26 | 0.68 to 7.53 | 0.18 | |||
| Sex | ||||||||
| Male | 29 | 5 | 1 | |||||
| Female | 25 | 7 | 1.82 | 0.58 to 5.74 | 0.31 | |||
| Body mass index | ||||||||
| ≤20 | 14 | 4 | 1.58 | 0.44 to 5.59 | ||||
| 20–25 | 28 | 6 | 1 | 0.77 | ||||
| 25–30 | 8 | 1 | 0.527 | 0.06 to 4.38 | ||||
| ≥30 | 4 | 1 | 1.16 | 0.14 to 9.68 | ||||
| Primary tumor location | ||||||||
| Right | 29 | 8 | 1 | |||||
| Left / rectum | 24 | 4 | 0.556 | 0.17 to 1.85 | 0.34 | |||
| Grade | ||||||||
| Well differentiated | 8 | 1 | 1 | |||||
| Moderately differentiated | 21 | 4 | 1.66 | 0.18 to 14.83 | ||||
| Poorly differentiated | 17 | 4 | 2.09 | 0.23 to 18.82 | 0.93 | |||
| Undifferentiated | 1 | 0 | – | |||||
| Stage | ||||||||
| II | 4 | 1 | 1 | |||||
| III | 17 | 3 | 0.79 | 0.08 to 7.63 | ||||
| IV | 25 | 6 | 1.08 | 0.13 to 9.01 | 0.91 | |||
| Number of metastatic sites | ||||||||
| 1–2 | 40 | 10 | 1 | |||||
| >2 | 14 | 2 | 0.61 | 0.13 to 2.79 | 0.52 | |||
| Number of anterior therapeutic sequences | ||||||||
| 1–2 | 28 | 5 | 1 | |||||
| >2 | 25 | 6 | 1.54 | 0.47 to 5.04 | 0.48 | |||
| Antibiotics before inclusion | ||||||||
| No | 45 | 9 | 1 | |||||
| Yes | 6 | 3 | 2.86 | 0.77 to 10.65 | 0.12 | |||
| Mutational status | ||||||||
| Wild type | 18 | 5 | 1 | 1 | ||||
| BRAF V600E-mutated | 9 | 4 | 1.70 | 0.46 to 6.34 | 0.68 | 0.16 to 2.94 | ||
| RAS-mutated | 27 | 3 | 0.33 | 0.08 to 1.39 | 0.10 | 0.32 | 0.07 to 1.34 | 0.30 |
| Origin of MMR deficiency | ||||||||
| Sporadic | 15 | 4 | 1 | |||||
| Lynch-related | 31 | 5 | 0.55 | 0.15 to 2.06 | 0.38 | |||
| Carcinoembryonic antigen (median) | ||||||||
| <12 | 28 | 4 | 1 | |||||
| ≥12 | 26 | 8 | 2.46 | 0.74 to 8.19 | 0.14 | |||
| Carcinoembryonic antigen* | ||||||||
| <60 | 41 | 5 | 1 | 1 | ||||
| ≥60 | 13 | 7 | 5.94 | 1.87 to 18.84 | 0.002 | 5.63 | 1.53 to 20.72 | 0.009 |
| dNLR | ||||||||
| <3 | 37 | 7 | 1 | |||||
| ≥3 | 17 | 5 | 1.75 | 0.556 to 5.525 | 0.34 | |||
N stands for number of (changed) ; P value stands for P-value (changed).
*Modeled with the restricted cubic splines method.
dNLR, a derived neutrophils/leukocytes minus neutrophils ratio; MMR, DNA mismatch repair.